The design of the novel semisynthetic aminoglycoside amikacin (1) as a consequence of the discovery of the naturally occurring antibiotic butirosin B (2) (Fig. 1 ) is well documented1-3). The discovery of this clinically useful drug constitutes a breakthrough in the fight against aminoglycoside resistant strains4).
In general, the hitherto most successful strategy to improve the chemotherapeutic properties of naturally occurring aminoglycoside antibiotics has been the selective acylation or alkylation of the 1-amino group at the 2-deoxystreptamine ring [5] [6] [7] [8] [9] [10] [11] A recent report 12 claiming that the AHBA side chain of butirosin B (2) and amikacin (1) could also be replaced by cyclic-7-amino-a-hydroxy acids led us to investigate the usefulness of 1L-1(OH), which obviously then, reacted with 12 and the methanol used as solvent, to yield 14.
The azido acid 9 was therefore converted first into its phthalimide ester 10 and then, condensed in situ with the 3,2',6'-tris-N-Boc-gentamicin C1a (12) , to give the desired intermediate 13 in 85 % yield.
Reaction occurred exclusively, as anticipated, with the 1-amino group. Catalytic hydrogenation of the azide 13, followed by deprotection using trifluoroacetic acid, led to the target molecule 15, isolated as the sulfate.
Confirmation of the structure of the desired new 1-N-acylgentamicin C1a (15) was obtained from a study of its chemical ionization mass and 13C NMR spectra. The mass spectrum of the per-N-acetylated derivative of 15 obtained by chemical ionization using isobutane21), exhibited a molecular ion peak (MH+) of very weak intensity at m/z 833 and structurally significant peaks corresponding to the fragment ions A, B and C at m/z 417, 213 and 205 respectively (Fig. 3 ).
The 13C NMR spectra of the derivative 15 and the parent gentamicin C1a (11) were measured under acidic conditions. The chemical shifts (Table 1) were assigned by comparison with those reported in the literature for gentamicin C1a (free base)22) taking into account both the known (3-protonation shift and N-acylation effects23-25). ppm), the resulting substituent effect (-3.6 ppm) under acidic conditions, is less marked than reported for the free base (-7 ppm)24). This is compatible with no i3-protonation shift observed for C-6, in the case of 1-N-acylation21).
Additional corroborative evidence for structure 15 is also provided by its C-2 chemical shift. As expected C-2, in 15 (31.8 ppm) resonates at lower field than in gentamicin C1a (11) (28.5 ppm). This is principally due to the fact that, in the 1-N-acyl derivatives, the usual /3-protonation shift (-8 ppm) observed for C-2 in unsubstituted aminoglycosides, decreases to approximatively -4. Table 2 .
The novel 1-N-acyl derivative 15 is less active against gentamicin sensitive Gram-negative microor- Table 1 . 13C NMR data of 11 and 15 in D2O at acidic pH with dioxane as an internal reference (3TMS= ddiox+67.4).
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Experimental
Melting points were determined on a Reichert hot-plate apparatus and are uncorrected. Optical rotations were measured on a "Quick" Roussel and Jouan polarimeter. IR spectra were obtained on a Perkin-Elmer 297 spectrometer. 13C NMR spectra were obtained on a Bruker WP-60 (15.08 MHz) or HX-90 (22.63 MHz) instruments. Chemical shifts (5) are reported with reference to tetramethylsilane. Mass spectra were recorded on either an A.E.I. MS-9 or an A.E.I. MS-50 spectrometer. TLC was performed on Schleicher and Schull plastic backed silica gel plates (F 1500 S 254); the plates were initially examined under UV light (254 and 366 nm) then developed with appropriate spray reagents. Column chromatography was effected, under low pressure, using Merck Kieselgel (Type 60) and the eluant given in parentheses. Evaporations were carried out at below 40'C using a Buchi rotary evaporator.
The microanalyses were performed in the analytical department of the I.C.S.N., Gif sur Yvette. 1L-1(OH),4/3,5-3-Azido-1,4,5-trihydroxycyclohexanecarboxylic 1,5-Lactone (7) A stirred mixture of the tosylate 6 (6 g), sodium azide (5 g, 4 equiv.) and NN-dimethylformamide (100 ml) was heated at 120°C for 24 hours. The solvent was evaporated in vacuo and the residue then poured into ice-water and extracted with ethyl acetate. The organic layer was evaporated and the solid residue was recrystallized from ethyl acetate -hexane (2: 1) to give the azide 7 (2. 1 L-l(OH),4/3,5-3-Azido-1,4,5-trihydroxycyclohexanecarboxylic Acid (9) A mixture of the azido-lactone 7 (3 g) and aqueous potassium hydroxide (30 ml, 1.1 equiv.) was stirred at room temperature; after 10 minutes, Amberlite IR-120(H+) (6 g) was added to convert the potassium salt 8 into the free acid 9 and the stirring was continued at 20'C for 30 minutes. The resin was filtered off and the aqueous filtrate was lyophilized to give the pure title compound 9 (3. To an ice cooled solution of the azide 9 (1 g) in N,N-dimethylformamide (20 ml) were added Nhydroxyphtalimide (0.83 g) and dicyclohexylcarbodiimide (1.2 g). After stirring for 3 hours, to the mixture, was added a solution of 13 (3.5 g) in N,N-dimethylformamide and the stirring was continued for an additional 3 hours. The precipitated dicyclohexylurea was filtered off and the filtrate was evaporated to dryness. Column chromatography on silica gel using chloroform -methanol -conc. ammonium hydroxide (15:4: 1) as the eluant, afforded the protected-1-N-acylated gentamicin C1a 13 which was recrystallized from chloroform-ether (3. (13) (0.4 g) in methanol (12 ml) was hydrogenated in the presence of Adams catalyst (50 mg) overnight. After removal of the catalyst, the filtrate was concentrated to dryness (400 mg) and the residue was dissolved in trifluroacetic acid (3 ml). After 2 minutes at 25°C, the trifluoroacetate salt of 15 was precipitated with ether and isolated by filtration. The target compound 15 was obtained as an amorphous solid, after passage over Amberlite IR-45 (OH-) resin followed by lyophilization.
The latter free base (250 mg) was dissolved in dry methanol (15 ml) and 1 N sulfuric acid was added until the pH reached 3. Then the solution was carefully poured into ice-cold, vigorously stirred ether (30 ml) and the stirring continued over 15 minutes. 
